Skip to content

Advanced Non-Invasive Diagnostics in Inflammatory Bowel Disease

A Comparative Study of the Diagnostic Validity of Ultrasound, Magnetic Resonance Imaging and Capsule Endoscopy of Both the Small and Large Intestine in Suspected Crohn's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03134586
Acronym
ANDI
Enrollment
153
Registered
2017-05-01
Start date
2016-06-30
Completion date
2020-10-23
Last updated
2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease

Keywords

Capsule endoscopy, Crohn's disease, Magnetic resonance enterography, Ileocolonoscopy, Bowel Ultrasound, diagnostic imaging

Brief summary

The purpose of this study is to determine whether Non-invasive endoscopic procedures (pillcam colon capsule endoscopy, PCCE) and non-ionizing radiological modalities (MR enterocolonography, MREC and ultrasound, US) - offer a sufficiently high diagnostic validity in patients with suspected CD compared to the traditional invasive approach using ileocolonoscopy with biopsies as first line diagnostic modality

Detailed description

This is a prospective, blinded, multicenter study of the diagnostic validity, inter-observer agreement, image quality and subjective experience of discomfort with PCCE, MREC and US in patients with suspected CD. Ileocolonoscopy serves as the diagnostic gold standard. Patients are recruited from 3 centers in the Region of Southern Denmark managing adult patients with inflammatory bowel diseases. Each patient goes through a standardized work-up including medical history, physical examination, C-reactive protein, fecal calprotectin, ileocolonoscopy, PCCE, MREC and US. All examinations are reviewed and described in a standardized fashion. The radiologists and physicians describing PCCE, MREC, and US are blinded to the findings at ileocolonoscopy and the other imaging modalities.

Interventions

OTHERDiagnostic imaging

Sponsors

Odense University Hospital
CollaboratorOTHER
Sygehus Lillebaelt
CollaboratorOTHER
Esbjerg Hospital - University Hospital of Southern Denmark
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

General criterion All of the following: * Clinical suspicion of CD * Age \> 15 years * Negative serologic markers for celiac disease, negative stool culture (or polymerase chain reaction) for pathogenic bacteria and a negative microscopy for intestinal parasites * Fecal calprotectin \> 50 mg/kg * Signed informed consent Clinical criterion Diarrhea and/or abdominal pain for more than 1 month (or repeated episodes of diarrhea and/or abdominal pain) associated with one or more of the following findings: (1) C-reactive protein (CRP) \>5 mg/L, (2) thrombocytosis (\> 400 x 109/L), anemia (hemoglobin \< 7.0 mmol/L for women and \< 8.0 mmol /L for men or a decrease \> 0.5 mmol/L compared to the usual level), (3) prolonged fever (\> 37.5 C for more than 2 weeks), (5) weight loss (≥ 3 kg or ≥ 5% compared to the normal body weight), (6) perianal abscess/fistula, or (7) a family history of inflammatory bowel disease.

Exclusion criteria

* Acute bowel obstruction * Intake of NSAIDs or acetylsalicylic acid ≤ 4 weeks before inclusion except prophylactic treatment with low dose Aspirin (≤ 150 mg per day) * Pregnancy or lactation * Alcohol or drug abuse * Known gastrointestinal disorder other than inflammatory bowel disease * Renal failure defined by a plasma-creatinine above the normal reference range * Claustrophobia, cardiac pacemaker or implanted magnetic foreign bodies that precludes MREC * Interpreter required or inability to understand the oral and written information * Colonoscopy contraindicated, performed within 3 months or unwillingness to go through colonoscopy

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD36 monthsSensitivity and specificity of PCCE, MREC and US for the diagnosis of CD located in the terminal ileum and colon (per patient & per segment). Ileocolonoscopy serves as gold standard
Correlation of disease severity36 monthsCorrelation of disease severity assessed with PCCE, MREC, US and ileocolonoscopy
Inter-observer agreement36 monthsInter-observer agreement with PCCE, MREC, US and ileocolonoscopy

Secondary

MeasureTime frameDescription
Diagnostic yield of proximal CD36 monthsDiagnostic yield of PCCE, MREC and US for CD located proximal to the terminal ileum
Utility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow36 monthsUtility of diffusion weighed magnetic resonance imaging (dw-MREC) and US Doppler flow (Limberg score): Sensitivity, specificity and correlation with endoscopic disease activity
Patients reported experience36 monthsPatients' subjective experience of discomfort during PCCE, MREC, US and ileocolonoscopy
Interobserver PCCE36 monthsSensitivity and specificity of PCCE with different reading protocols

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026